The United States of America, as Represented by the Secretary, Department of Health and Human Services

Universitätsklinikum Freiburg

University of Freiburg

Klaus Mross

William Douglas Figg

Alex Sparreboom

Tristan M Sissung

Dirk Behringer

Stephan Mielke

William D Figg

Stephen Mielke

The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G&#x3e;T/A and 3435C&#x3e;T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.

ABCB1 genotyping to predict microtubule-stabilizing-agent-induced toxicity

Growing community of inventors

Freiburg, Germany

Klaus Mross